HK Stock Market Move | MOST Kwai Chung (01716) rises nearly 42% to reach a new high. Ma Liyang responds for the first time regarding the acquisition matter, and plans to build the company into a dual capital platform system in the future.
Maoji Kuiyong (01716) rose nearly 42% in the afternoon, hitting a high of 6.16 Hong Kong dollars during trading, setting a new high for the year. As of the time of writing, it has risen 38.5%, trading at 5.9 Hong Kong dollars, with a turnover of 64.3943 million Hong Kong dollars.
MOST KWAI CHUNG (01716) rose nearly 42% in the afternoon, hitting a high of 6.16 Hong Kong dollars during the trading session to set a new high for the year. As of the time of writing, it had risen by 38.5% to 5.9 Hong Kong dollars, with a trading volume of 64.3943 million Hong Kong dollars.
On the news front, on April 24th, Ma Liyang said in a phone call, "The acquisition of MOST KWAI CHUNG is an independent capital operation and will not compete with Indium Target Advanced Materials (Harbin) Co. There are currently no plans to have MOST KWAI CHUNG operate the indium industry project." This conversation was Ma Liyang's first response after completing the acquisition of 65% of the shares of MOST KWAI CHUNG, a Hong Kong-listed company. Ma Liyang also emphasized that this acquisition is an independent capital operation and did not use any funds from the listed company Indium Target Advanced Materials (Harbin) Co. Both companies remain completely independent in terms of assets, finances, personnel, and business, and there is no competition between them.
Ma Liyang stressed that the underlying logic of this acquisition is to build a "A-share + overseas" dual capital platform system. The A-share platform will be based on the indium industry chain system built by Ma Liyang over the years, relying on mainland capital market resources to create a high-tech new key material business system with the indium industry chain at its core. The overseas platform is aimed at establishing a financing and capital operation system for global capital markets, efficiently raising funds from overseas capital markets, and efficiently deploying them in overseas projects.
Related Articles

J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.

UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.

LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.

UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.

LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.






